Safety and efficacy of adjuvant pegylated interferon therapy for metastatic tumor antigen 1-positive hepatocellular carcinoma

Cancer

Volumn 119, Issue 12, 2013, Pages 2239-2246

  Lee, Danbi ^a   Chung, Young Hwa ^a   Kim, Jeong A ^a   Park, Won Hyung ^a   Jin, Young Joo ^a   Shim, Ju Hyun ^a   Ryu, Soo Hyung ^b   Jang, Myoung Kuk ^c   Yu, Eunsil ^a   Lee, Young Joo ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Inje University College of Medicine   (South Korea)

^c Hallym University College of Medicine   (South Korea)

Author keywords

adjuvant therapy; curative resection; hepatocellular carcinoma; metastatic tumor antigen 1; pegylated interferon; recurrence

Indexed keywords

METASTATIC TUMOR ANTIGEN 1; PEGINTERFERON ALPHA2B; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CHILL; CONTROLLED STUDY; DISTANT METASTASIS; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLU LIKE SYNDROME; HAIR LOSS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; IMMUNOHISTOCHEMISTRY; INSOMNIA; KIDNEY FAILURE; LIVER CELL CARCINOMA; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; MOOD DISORDER; MYALGIA; NEUTROPENIA; PERITONEUM METASTASIS; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTOPENIA; THYROID DISEASE; TUMOR VOLUME; XEROSTOMIA;

ADULT; AGED; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; CHEMOTHERAPY, ADJUVANT; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B; HEPATITIS C; HISTONE DEACETYLASES; HUMANS; INTERFERON-ALPHA; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; REPRESSOR PROTEINS; SURVIVAL RATE;

EID: 84878590204     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28082     Document Type: Article

References (38)

1. Bosch FX, Ribes J, Diaz M, Cleries R,. Primary liver cancer: worldwide incidence and trends. Gastroenterology. 2004; 127: S5-S16.
2. Zhang CH, Xu GL, Jia WD, Ge YS,. Effects of interferon alpha treatment on recurrence and survival after complete resection or ablation of hepatocellular carcinoma: a meta-analysis of randomized controlled trials. Int J Cancer. 2009; 124: 2982-2988.
3. Nagorney DM, van Heerden JA, Ilstrup DM, Adson MA,. Primary hepatic malignancy: surgical management and determinants of survival. Surgery. 1989; 106: 740-748; discussion 748-749.
4. Mazzaferro V, Romito R, Schiavo M, et al. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology. 2006; 44: 1543-1554.
5. Ueshima K, Kudo M, Nagai T, et al. Combination therapy with S-1 and pegylated interferon alpha for advanced hepatocellular carcinoma. Oncology. 2008; 75 (suppl 1): 106-113.
6. Adachi E, Maeda T, Matsumata T, et al. Risk factors for intrahepatic recurrence in human small hepatocellular carcinoma. Gastroenterology. 1995; 108: 768-775.
7. Kumada T, Nakano S, Takeda I, et al. Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma. Hepatology. 1997; 25: 87-92.
8. Chen MF, Jeng LB, Lee WC, Chen TC,. Surgical results in patients with dual hepatitis B- and C-related hepatocellular carcinoma compared with hepatitis B- or C-related hepatocellular carcinoma. Surgery. 1998; 123: 554-559.
9. Takenaka K, Yamamoto K, Taketomi A, et al. A comparison of the surgical results in patients with hepatitis B versus hepatitis C-related hepatocellular carcinoma. Hepatology. 1995; 22: 20-24.
10. Chong CC, Lee KF, Ip PC, et al. Pre-operative predictors of post-hepatectomy recurrence of hepatocellular carcinoma: can we predict earlier? Surgeon. 2012; 10: 260-266.
11. Hanazaki K, Kajikawa S, Shimozawa N, et al. Survival and recurrence after hepatic resection of 386 consecutive patients with hepatocellular carcinoma. J Am Coll Surg. 2000; 191: 381-388.
12. Hung HH, Lei HJ, Chau GY, et al. Milan criteria, multi-nodularity, and microvascular invasion predict the recurrence patterns of hepatocellular carcinoma after resection [published online ahead of print December 6, 2012]. J Gastrointest Surg. 2012.
13. Toh Y, Nicolson GL,. The role of the MTA family and their encoded proteins in human cancers: molecular functions and clinical implications. Clin Exp Metastasis. 2009; 26: 215-227.
14. Kumar R, Wang RA, Bagheri-Yarmand R,. Emerging roles of MTA family members in human cancers. Semin Oncol. 2003; 30: 30-37.
15. Ryu SH, Chung YH, Lee H, et al. Metastatic tumor antigen 1 is closely associated with frequent postoperative recurrence and poor survival in patients with hepatocellular carcinoma. Hepatology. 2008; 47: 929-936.
16. Moon WS, Chang K, Tarnawski AS,. Overexpression of metastatic tumor antigen 1 in hepatocellular carcinoma: relationship to vascular invasion and estrogen receptor-alpha. Hum Pathol. 2004; 35: 424-429.
17. Kim KR, Moon HE, Kim KW,. Hypoxia-induced angiogenesis in human hepatocellular carcinoma. J Mol Med. 2002; 80: 703-714.
18. Ikeda K, Saitoh S, Suzuki Y, et al. Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus: a pilot study. Cancer. 1998; 82: 827-835.
19. Nakaji M, Yano Y, Ninomiya T, et al. IFN-alpha prevents the growth of pre-neoplastic lesions and inhibits the development of hepatocellular carcinoma in the rat. Carcinogenesis. 2004; 25: 389-397.
20. Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med. 1999; 131: 174-181.
21. Sun HC, Tang ZY, Wang L, et al. Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. J Cancer Res Clin Oncol. 2006; 132: 458-465.
22. Lee SH, Chung YH, Kim JA, et al. Single nucleotide polymorphisms associated with metastatic tumour antigen 1 overexpression in patients with hepatocellular carcinoma. Liver Int. 2012; 32: 457-466.
23. Hagiwara S, Kudo M, Ueshima K, et al. The cancer stem cell marker CD133 is a predictor of the effectiveness of S1+ pegylated interferon alpha-2b therapy against advanced hepatocellular carcinoma. J Gastroenterol. 2011; 46: 212-221.
24. Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. The Cancer of the Liver Italian Program (CLIP) Investigators. Hepatology. 2000; 31: 840-845.
25. Fan ST, Lo CM, Liu CL, et al. Hepatectomy for hepatocellular carcinoma: toward zero hospital deaths. Ann Surg. 1999; 229: 322-330.
26. Uenishi T, Nishiguchi S, Tanaka S, Yamamoto T, Takemura S, Kubo S,. Response to interferon therapy affects risk factors for postoperative recurrence of hepatitis C virus-related hepatocellular carcinoma. J Surg Oncol. 2008; 98: 358-362.
27. Baker DE,. Pegylated interferon plus ribavirin for the treatment of chronic hepatitis C. Rev Gastroenterol Disord. 2003; 3: 93-109.
28. Yano H, Ogasawara S, Momosaki S, et al. Growth inhibitory effects of pegylated IFN alpha-2b on human liver cancer cells in vitro and in vivo. Liver Int. 2006; 26: 964-975.
29. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD,. How cells respond to interferons. Annu Rev Biochem. 1998; 67: 227-264.
30. Pestka S, Langer JA, Zoon KC, Samuel CE,. Interferons and their actions. Annu Rev Biochem. 1987; 56: 727-777.
31. Ikeda K, Saitoh S, Arase Y, et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology. 1999; 29: 1124-1130.
32. Ikeda K, Arase Y, Saitoh S, et al. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology. 2000; 32: 228-232.
33. Mazzella G, Accogli E, Sottili S, et al. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol. 1996; 24: 141-147.
34. Sakaguchi Y, Kudo M, Fukunaga T, Minami Y, Chung H, Kawasaki T,. Low-dose, long-term, intermittent interferon-alpha-2b therapy after radical treatment by radiofrequency ablation delays clinical recurrence in patients with hepatitis C virus-related hepatocellular carcinoma. Intervirology. 2005; 48: 64-70.
35. Breitenstein S, Dimitroulis D, Petrowsky H, Puhan MA, Mullhaupt B, Clavien PA,. Systematic review and meta-analysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis. Br J Surg. 2009; 96: 975-981.
36. Kudo M,. Impact of interferon therapy after curative treatment of hepatocellular carcinoma. Oncology. 2008; 75 (suppl 1): 30-41.
37. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D,. Global cancer statistics. CA Cancer J Clin. 2011; 61: 69-90.
38. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology. 1998; 28: 751-755.